Key result
Serum neuropilin-1 (NRP-1) discriminated hepatocellular carcinoma from healthy subjects (AUC 0.992) and patients with cirrhosis (AUC 0.801), performing better than ANG-2.
Why the study?
The diagnostic value of serum angiogenic markers neuropilin-1 and angiopoietin-2 in hepatocellular carcinoma and their relation to tumor characteristics needed assessment.
Do serum NRP-1 and ANG-2 levels accurately diagnose hepatocellular carcinoma compared to cirrhosis and healthy controls?
Observational (n=149)
Do serum NRP-1 and ANG-2 levels accurately diagnose hepatocellular carcinoma compared to cirrhosis and healthy controls?
Serum NRP-1 is a potential diagnostic biomarker for hepatocellular carcinoma, outperforming ANG-2, and correlates with advanced tumor characteristics.
Answers are grounded in this paper and cite their sources.
Serum NRP-1 may support HCC diagnosis with AFP; leaves open clinical adoption pending prospective validation.
This study aimed to assess the diagnostic value of two serum angiogenetic markers neuropilin-1 (NRP-1) and angiopoietin-2 (ANG-2) in patients with hepatocellular carcinoma (HCC) and their relation to tumor characteristics. 149 subjects were recruited and divided into 50 patients with recently diagnosed HCC, 49 patients with cirrhosis on top of hepatitis C virus infection, and 50 healthy subjects. Serum NRP-1 and ANG-2 were estimated by ELISA. Alpha-fetoprotein (AFP) levels were measured using fluorescence immunoassay. Serum NRP-1 and ANG-2 levels were significantly higher in patients with HCC (2221.8±1056.6 pg/mL and 3018.5±841.4 pg/mL) than healthy subjects (219.3±61.8 pg/mL and 2007.7±904.8 pg/mL) and patients with cirrhosis (1108.9±526.6 pg/mL and 2179.1±599.2 pg/mL), respectively. In multivariate logistic regression analysis, NRP-1 and AFP were the only independent factors of HCC development and correlated positively with each other (r=0.781, p<0.001). Receiver operating characteristic curve analysis showed that the area under the curve (AUC) of NRP-1 was higher than that of ANG-2 in discriminating HCC from patients with cirrhosis (0.801 vs 0.748, p=0.250) and healthy subjects (0.992 vs 0.809, p<0.001). The AUC of NRP-1 was detected to be increased (0.994) when combined estimation with AFP was performed. Elevated serum NRP-1 and ANG-2 levels were detected in patients with HCC with tumor numbers >3, tumor size ≥5 cm, tumor stages B/C according to the Barcelona Clinic Liver Cancer staging system, vascular invasion, and distant metastasis. In conclusion, NRP-1 is a potential serological marker for HCC diagnosis and is better than ANG-2. It is feasible to be estimated in combination with AFP to enhance its diagnostic power. High serum NRP-1 and ANG-2 levels are associated with advanced HCC tumor characteristics.
No takes yet. Share an insight, caveat, or question.
Ghafar et al. (2021) conducted an observational in Hepatocellular carcinoma (n=149). Serum neuropilin-1 (NRP-1) and angiopoietin-2 (ANG-2) vs. Healthy subjects and patients with cirrhosis was evaluated on Discrimination of hepatocellular carcinoma from healthy subjects (AUC 0.992, p=<0.001). Serum neuropilin-1 (NRP-1) discriminated hepatocellular carcinoma from healthy subjects (AUC 0.992) and patients with cirrhosis (AUC 0.801), performing better than ANG-2.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: